Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › DSGN
SR ONE CAPITAL MANAGEMENT, LP position in DSGN
DESIGN THERAPEUTICS INC · Health Care
SR ONE CAPITAL MANAGEMENT, LP reported holding 6,526,476 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$94.4M, representing 9.09% of its reported portfolio and ranking #5 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SR ONE CAPITAL MANAGEMENT, LP's DSGN position evolved
SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in DSGN in Q3 2023 at 6,526,476 shares (US$15.4M). The position peaked in Q2 2026 at 6,526,476 shares, worth US$94.4M. Across 12 filings, SR ONE CAPITAL MANAGEMENT, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 6,526,476 shares valued at US$94.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.53M | $15.40M | New |
| Q4 2023 | 6.53M | $17.30M | Hold |
| Q1 2024 | 6.53M | $26.30M | Hold |
| Q2 2024 | 6.53M | $21.86M | Hold |
| Q3 2024 | 6.53M | $35.11M | Hold |
| Q4 2024 | 6.53M | $40.27M | Hold |
| Q1 2025 | 6.53M | $25.19M | Hold |
| Q2 2025 | 6.53M | $21.99M | Hold |
| Q3 2025 | 6.53M | $49.14M | Hold |
| Q4 2025 | 6.53M | $61.22M | Hold |
| Q1 2026 | 6.53M | $69.44M | Hold |
| Q2 2026 | 6.53M | $94.44M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M), Trails Edge Capital Partners, LP (US$29.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- Logos Global Management LP 3.00M sh · $43.41M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M sh · $38.76M · Q2 2026
- Trails Edge Capital Partners, LP 2.00M sh · $28.96M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K sh · $12.52M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 282.56K sh · $4.09M · Q2 2026
- KVP Capital Advisors, LP 185.00K sh · $2.68M · Q2 2026
- Elmind Capital, LP 107.90K sh · $1.56M · Q2 2026
More on SR ONE CAPITAL MANAGEMENT, LP
FAQ
How long has SR ONE CAPITAL MANAGEMENT, LP held DSGN?
SR ONE CAPITAL MANAGEMENT, LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is SR ONE CAPITAL MANAGEMENT, LP's current position in DSGN?
As of Q2 2026, SR ONE CAPITAL MANAGEMENT, LP holds 6.53M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $94.44M, representing 9.09% of its reported portfolio and ranking #5.
Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling DSGN?
In the latest 13F filing (Q2 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in DSGN. The position peaked in Q2 2026 at 6.53M shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include Logos Global Management LP, BAKER BROS. ADVISORS LP, Trails Edge Capital Partners, LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.